Bortezomib Use for a Critically Ill Patient with Angioimmunoblastic T-Cell Lymphoma

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="6"><hr/></td></tr><tr class="thead"><td class="align_left"> </td><td class="align_center">Age/Sex</td><td class="align_center">Treatment</td><td class="align_center">Response</td><td class="align_center">Duration of effectiveness</td><td class="align_center">Reference</td></tr><tr><td class="thead-hr" colspan="6"><hr/></td></tr><tr><td class="align_left">case1</td><td class="align_center">63/Female</td><td class="align_center">Bortezomib and dexamethasone</td><td class="align_center">Lymphadenopathies reduced in size</td><td class="align_center">4 months</td><td class="align_center">14</td></tr><tr><td class="align_left" colspan="6"><hr/></td></tr><tr><td class="align_left">case2</td><td class="align_center">76/Female</td><td class="align_center">Bortezomib, mitoxantrone, and dexamethasone</td><td class="align_center">Disappearance of lymphadenopathy</td><td class="align_center">18 months</td><td class="align_center">15</td></tr><tr class="table-tr"><td colspan="6"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Previous case reports of bortezomib use in angioimmunoblastic T-cell lymphoma.</div>

Case Reports in Hematology

tab1

Table 1

Table 1: Bortezomib Use for a Critically Ill Patient with Angioimmunoblastic T-Cell Lymphoma 